FMCBy Calypso Research8 min read

FMC Corp (FMC) Q4 2025 Earnings Analysis

FMC's Earnings Take a Dip with a 13.1% Sudden Plunge

Key Takeaways

FMC Corp (FMC) reported Q4 2025 earnings with revenue of $1.1B, representing a -7.2% year-over-year change. The stock moved -13.1% on earnings day.

The bull case: Successful execution of asset sales, cost restructuring, and R&D-driven growth allows FMC to deleverage by $1B, stabilize Rynaxypyr and the core portfolio, and unlock the high-margin new AI pipeline, potentially enhanced by a value-creating strategic transaction.

The bear case: Persistent generic pressure, execution risk on manufacturing and registrations, and any stumble in asset sales or refinancing could undermine 2026 guidance, strain the balance sheet, and force a sale or recapitalization at depressed valuations with limited recovery in earnings power.

Financial Highlights

  • Revenue: $1.1B (-7.2% YoY)
  • Gross Profit: $483M (42.5% margin, +0.8% YoY)
  • Operating Income: $-1.7B (-146.0% margin, -169.1% YoY)
  • Net Income: $-1.7B
  • TTM Revenue: $3.5B

Stock Performance

  • Earnings Day Move: -13.1%
  • Year-to-Date: -4.7%
  • 1-Year Return: -64.0%
  • vs. S&P 500 (since earnings): -3.3%
  • vs. Nasdaq (since earnings): -0.2%

View live FMC data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from FMC Corp's Q4 2025 earnings call:

Strategic Review vs. Base Plan: Full Company Sale, Timing, and Structure

Sentiment: Mixed

"So that discussion with the board led us to say we need to pursue two paths. Path number one, the plan I presented to you, path number two, an entire sale of the company. And for this, we are getting structured. We've hired advisers, bank and legal, and the process is being put in place right now." — Pierre Brondeau
"From a probability level today, I think the two highest probabilities we have in front of us, one is the base plan, which includes a licensing, a sale of assets, and the sale of India. The other one is the full sale of the company... right now, we are focusing on two paths as the principal actions we are taking." — Pierre Brondeau

Visibility and Credibility of 2027–2028 Mid-Teens EBITDA Growth

Sentiment: Mixed

"So delivering a 15% EBITDA growth in 2027 has to be done by a continuation of what we have done over the last two years on the growth platform, which we are confident we can do, and really get a core product competitive from a manufacturing standpoint, which we expect to do by 2027." — Pierre Brondeau
"I would assume that you're thinking 2026 is a bottom for the company... I also believe that getting through 2026, the way we are doing it, will create growth starting in 2027 and 2028... I think the '26 plan is robust and will put us in a good place in '27." — Pierre Brondeau

Rynaxypyr Strategy in a Post‑Patent, Generic-Heavy World

Sentiment: Mixed

"We also have a high level of confidence in our ability to keep earnings flat from 2025 for branded Rynaxypyr, and we're already seeing how this is going to be deployed... The number two is sales to a diamide partner... those are the two factors today which are creating the most headwind in 2026 and which are being addressed to go away in 2027." — Pierre Brondeau
"You cannot make a straight calculation of lower price, higher volume, where do we land in profitability? Because you have a change in the mix which is enormous... I believe for Rynaxypyr in 2026, 50% of our sales will shift to advanced formulation... there is a very large part of the portfolio which doesn't see lower price." — Pierre Brondeau

Core (Non‑Rynaxypyr) Portfolio Competitiveness and Execution Risk

Sentiment: Mixed

"The first one is the core portfolio. We know that we do have about a billion dollars of production, which is not cost-competitive, and for which we are being challenged to grow and losing market share... That's the number one contributor, and that's where we have a high level of focus." — Pierre Brondeau
"We have one thing to fix. It's the core portfolio. We know how to do it. It's ongoing. The plan is in place. And it started. So why am I so confident? It's because the number of things we have to fix is limited. It's one thing. The rest is in place. The problem is this thing we have to fix, we better fix it because it's big." — Pierre Brondeau

Balance Sheet, Leverage, and Refinancing Risk Through 2026

Sentiment: Mixed

"Look, we have $500 million bonds maturing in October... our attempt is to refinance them in advance of their maturity... fallback, we can absorb that into the existing revolving capacity... our intent is to replace them with new financing well in advance of that." — Andrew Sandifer
"We have a plan to reduce that debt by a billion dollars this year through a mix of asset sales, licensing agreements, etc. We have very strong confidence in that plan... We asked for a very high covenant, six times, to allow us the flexibility to work through the things that we need to do in 2026." — Andrew Sandifer

Bull Case

Successful execution of asset sales, cost restructuring, and R&D-driven growth allows FMC to deleverage by $1B, stabilize Rynaxypyr and the core portfolio, and unlock the high-margin new AI pipeline, potentially enhanced by a value-creating strategic transaction.

Bear Case

Persistent generic pressure, execution risk on manufacturing and registrations, and any stumble in asset sales or refinancing could undermine 2026 guidance, strain the balance sheet, and force a sale or recapitalization at depressed valuations with limited recovery in earnings power.

Looking Ahead

With revenue declining -7.2% year-over-year, investors will be watching for signs of a turnaround at FMC Corp, particularly around strategic Review vs. Base Plan: Full Company Sale, Timing, and Structure. With operating margins at -146.0%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was FMC Corp's revenue in Q4 2025?

FMC Corp reported Q4 2025 revenue of $1.1B, representing a -7.2% year-over-year change.

Did FMC Corp beat earnings expectations in Q4 2025?

The stock declined -13.1% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Successful execution of asset sales, cost restructuring, and R&D-driven growth allows FMC to deleverage by $1B, stabilize Rynaxypyr and the core portfolio, and unlock the high-margin new AI pipeline, potentially enhanced by a value-creating strategic transaction.

What is the bull case for FMC stock?

The bull case for FMC centers on: Successful execution of asset sales, cost restructuring, and R&D-driven growth allows FMC to deleverage by $1B, stabilize Rynaxypyr and the core portfolio, and unlock the high-margin new AI pipeline, potentially enhanced by a value-creating strategic transaction.

What is the bear case for FMC stock?

The bear case for FMC centers on: Persistent generic pressure, execution risk on manufacturing and registrations, and any stumble in asset sales or refinancing could undermine 2026 guidance, strain the balance sheet, and force a sale or recapitalization at depressed valuations with limited recovery in earnings power.

How has FMC stock performed since its Q4 2025 earnings?

FMC moved -13.1% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +3.3% since earnings. Year-to-date, the stock has returned -4.7%.

Browse all 400+ earnings reports →

Learn More

Analyze FMC in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for FMC Corp and 400+ other stocks, explore the full platform.

Open FMC on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.